Change of Director's Interest Notice x3
Released
Released
Announcement PDF
ASX Announcement
31 May 2021
ASX Market Announcements
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000
APPENDIX 3Y
Melbourne, Australia, 31 May 2021 - Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”), a company that develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called TPM®, submits the Appendix 3Y of the following Directors:
a) Dr Gregory Collier
b) Dr Ross Murdoch
c) Mr Matthew McNamara
For enquiries, please contact
Ms Melanie Leydin
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health
products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is
derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the
solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market, including the recently announced application of TPM® to cannabinoids. The Company
is also developing TPM® to enhance feed efficiency and health of livestock.
See more here - avecho.com.au
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Avecho Biotechnology Limited
ABN
32 056 482 403
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Date of last notice
Gregory Collier
31 October 2017
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
Direct
N/A
31 May 2021
Indirect
Beacon Super Fund Pty Ltd
1. 2,000,000 fully paid ordinary shares (AVE)
2. 2,250,000 unlisted options (AVEAS)
Gregory Collier is a Director of Beacon Super
Fund Pty Ltd
Class
Number acquired
Number disposed
+ See chapter 19 for defined terms.
01/01/2011
Unlisted options exercisable at $0.0169 each
and expiring 42 months from 31 May 2021, i.e.,
on 29 November 2024 (AVEAV)
5,990,465
Nil
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Nil
No. of securities held after change
Indirect
Beacon Super Fund Pty Ltd
1. 2,000,000 fully paid ordinary shares (AVE)
2. 2,250,000 unlisted options (AVEAS)
Note: If consideration is non-cash, provide details and estimated
valuation
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Direct
1. 5,990,465 unlisted options exercisable at
$0.0169 each and expiring 42 months from
31 May 2021, i.e., on 29 November 2024
(AVEAV)
Unlisted options granted under the Company’s
Equity Incentive Plan approved at Annual
General Meeting on 31 May 2021.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
N/A
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
N/A
N/A
N/A
N/A
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Avecho Biotechnology Limited
ABN
32 056 482 403
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Date of last notice
Ross Murdoch
2 March 2020
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Date of change
No. of securities held prior to change
Class
Number acquired
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Direct
N/A
31 May 2021
Direct
1,666,667 fully paid ordinary shares (AVE)
Unlisted options exercisable at $0.0169 each and
expiring 42 months from 31 May 2021, i.e., on 29
November 2024 (AVEAV)
3,993,644
Nil
Nil
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Direct
1. 1,666,667 fully paid ordinary shares (AVE)
2. 3,993,644 unlisted options exercisable at
$0.0169 each and expiring 42 months from
31 May 2021, i.e., on 29 November 2024
(AVEAV)
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation
in buy-back
Unlisted options granted under the Company’s
Equity Incentive Plan approved at Annual
General Meeting on 31 May 2021.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
N/A
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
N/A
N/A
N/A
N/A
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Avecho Biotechnology Limited
ABN
32 056 482 403
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Date of last notice
Matthew Patrick McNamara
13 January 2020
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
Class
Number acquired
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
+ See chapter 19 for defined terms.
01/01/2011
Indirect
Mlaks Pty Ltd ITF M and L McNamara Super
Fund
Matthew McNamara is a beneficiary of the fund
31 May 2021
Nil
Unlisted options exercisable at $0.0169 each
and expiring 42 months from 31 May 2021, i.e.,
on 29 November 2024 (AVEAV)
3,993,644
Nil
Nil
Indirect
Mlaks Pty Ltd ITF M and L McNamara Super
Fund
3,993,644 Unlisted options exercisable at
$0.0169 each and expiring 42 months from 31
May 2021, i.e., on 29 November 2024 (AVEAV)
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Unlisted options granted under the Company’s
Equity Incentive Plan approved at Annual
General Meeting on 31 May 2021.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
N/A
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
N/A
N/A
N/A
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Share your feedback
Discover